A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Tea will be served at 10:15 a.m., immediately preceding the seminar.AudienceThis seminar is open to the research community.

Tea will be served at 10:15 a.m., immediately preceding the seminar.AudienceThis seminar is open to the research community.

Mara Sherman, PhD, was awarded the Mark Foundation 2025 Emerging Leader Award, which honored five early-career scientists ...

Zenocutuzumab is a novel bispecific antibody designed by Merus, N.V. In a multicenter global phase 2 clinical trial led by MSK gynecologic medical oncologist and early drug development specialist ...

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

Tea will be served at 1:45 p.m., immediately preceding the seminar.AudienceThis seminar is open to the research community.

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Research at MSK Our research impact Research topics Core facilities & resources ...